Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Monopar Therapeutics from "strong sell" to "sell", making it the latest analyst update on the stock.
• Analyst sentiment remains broadly positive overall, with two Strong Buy ratings and ten Buy ratings; MarketBeat shows an average rating of "Buy" and an average target price of $107.00.
• Monopar recently reported a Q1 EPS loss of $0.61, missing consensus estimates, while the stock opened at $63.58 and has traded between $28.40 and $105.00 over the past 52 weeks.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a note issued to investors on Saturday.

MNPR has been the topic of a number of other research reports. Morgan Stanley started coverage on Monopar Therapeutics in a research report on Friday, January 9th. They issued an "overweight" rating and a $115.00 target price on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Finally, BTIG Research reissued a "buy" rating and set a $104.00 price target on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $107.00.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $63.58 on Friday. The stock's 50-day simple moving average is $56.04 and its 200 day simple moving average is $66.46. The company has a market cap of $425.99 million, a P/E ratio of -34.93 and a beta of 1.49. Monopar Therapeutics has a 52-week low of $28.40 and a 52-week high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its earnings results on Friday, March 27th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.10). As a group, equities analysts predict that Monopar Therapeutics will post -4.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the third quarter worth approximately $28,000. BNP Paribas Financial Markets grew its position in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock valued at $57,000 after purchasing an additional 349 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $65,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $86,000. Finally, JPMorgan Chase & Co. grew its position in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after purchasing an additional 1,821 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.